CJC-1295 No DAC & Ipamorelin Dosage for GH Release 2026

Research published by Jetté et al. in the Journal of Clinical Endocrinology & Metabolism found that combining GHRH analogs (like CJC-1295 no DAC) with GHRP-2 or GHRP-6 amplified growth hormone release by 300–500% compared to either peptide alone. But only when both peptides were dosed above receptor saturation thresholds. Most protocols floating around Reddit or forum boards recommend 50–100mcg 'to test tolerance,' which is below the threshold where synergy kicks in. You're not amplifying GH. You're wasting both compounds.

Our team has worked with research facilities running peptide protocols for over a decade. The gap between effective dosing and ineffective dosing comes down to understanding receptor mechanics most amateur guides completely ignore.

What is the best CJC-1295 no DAC & Ipamorelin dosage for synergistic GH release in 2026?

The best CJC-1295 no DAC & Ipamorelin dosage for synergistic GH release is 100–200mcg of each peptide, injected subcutaneously 30–60 minutes before sleep, 5–7 days per week. This range saturates both GHRH receptors (via CJC-1295) and ghrelin receptors (via Ipamorelin) simultaneously, producing peak serum GH levels 3–5× baseline within 30 minutes of administration without elevating cortisol or prolactin.

Yes, the stack amplifies GH secretion beyond what either peptide achieves alone. But the mechanism isn't additive, it's multiplicative. CJC-1295 no DAC (a modified growth hormone releasing hormone analog) binds to GHRH receptors on somatotrophs in the anterior pituitary, priming them to release GH. Ipamorelin (a selective ghrelin receptor agonist) then acts on the same cells via a separate receptor pathway, amplifying the GH pulse already initiated by the GHRH signal. The result is a single massive GH pulse. Not two separate smaller pulses. This article covers exactly how receptor saturation determines efficacy, what preparation and timing mistakes eliminate synergy entirely, and what dosing protocols advanced research facilities actually use.

Mechanism: How CJC-1295 and Ipamorelin Create Synergistic GH Release

CJC-1295 no DAC is a synthetic analog of growth hormone releasing hormone (GHRH) with a modified peptide sequence that extends its half-life to approximately 30 minutes. Long enough to saturate pituitary GHRH receptors but short enough to avoid tachyphylaxis (receptor desensitization) that plagues the DAC version. When administered subcutaneously, it binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, triggering intracellular cAMP signaling that mobilizes intracellular calcium stores. This calcium influx primes vesicles containing pre-synthesized GH for exocytosis. The cells are loaded and ready to fire.

Ipamorelin acts on ghrelin receptors (GHS-R1a) on those same somatotroph cells. Unlike earlier GHRPs (GHRP-2, GHRP-6, Hexarelin), Ipamorelin is highly selective. It doesn't activate cortisol or prolactin pathways at therapeutic doses. When both peptides saturate their respective receptors simultaneously, the result is a coordinated amplification: GHRH primes the GH release machinery, ghrelin receptor activation magnifies the signal, and the pituitary dumps significantly more GH than either peptide alone could trigger.

The synergy is dose-dependent. Below 100mcg of either peptide, receptor occupancy is incomplete. You get partial activation but not full synergistic amplification. Between 100–200mcg of each, both receptor populations saturate within 15–20 minutes of subcutaneous injection, producing peak GH levels at 30–45 minutes post-administration. Above 300mcg per peptide, additional GH release plateaus while side effect risk (transient hyperglycemia, water retention) increases. The therapeutic window is narrow and specific.

Dosage Protocols: Clinical Standards vs Research Applications

Clinical trials investigating GHRH-GHRP combinations consistently used 1–2mcg/kg body weight for each peptide, administered subcutaneously. For a 75kg individual, that translates to 75–150mcg of CJC-1295 no DAC and 75–150mcg of Ipamorelin per injection. Research facilities working with performance or anti-aging protocols typically standardize at 100mcg of each peptide for baseline responders, escalating to 200mcg each for individuals showing suboptimal GH response at the lower dose.

Timing matters as much as dose. GH secretion naturally peaks during deep slow-wave sleep (stages 3 and 4 of NREM sleep), which typically occurs 60–90 minutes after sleep onset. Administering the peptide stack 30–60 minutes before bed synchronizes the exogenous GH pulse with endogenous nocturnal secretion, amplifying the overnight anabolic window. Morning or midday dosing produces measurable GH elevation but misses the synergistic effect with natural sleep-related GH pulses.

Frequency protocols vary by application. For metabolic health or anti-aging research, 5 days per week (Monday through Friday, weekends off) prevents receptor downregulation while maintaining elevated weekly GH exposure. For performance-focused research, 7-day protocols are common but require periodic washout periods (2 weeks off every 12 weeks) to reset receptor sensitivity. Split dosing (morning + evening) doubles injection frequency without increasing efficacy. The pituitary's refractory period after a GH pulse means the second dose within 8–12 hours produces diminished response.

Reconstitution, Storage, and Administration: Where Most Protocols Fail

Lyophilized CJC-1295 no DAC and Ipamorelin arrive as white powder in sealed vials. They must be reconstituted with bacteriostatic water before injection. The critical error most users make is injecting air into the vial while drawing the reconstituted solution. Each time you push air in to equalize pressure, you create a pressure differential that pulls contaminants backward through the needle on subsequent draws. The correct technique: insert the needle, invert the vial, and draw slowly without injecting air. The slight vacuum created is harmless and prevents contamination.

Unreconstituted lyophilized peptides stored at −20°C remain stable for 24–36 months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation. The peptide sequence unfolds and loses receptor-binding affinity. A vial left out overnight isn't 'less potent'. It's essentially inactive. If you travel, use a purpose-built medication cooler (FRIO wallets use evaporative cooling and maintain 2–8°C for 48 hours without ice or electricity).

Subcutaneous injection sites with optimal absorption: lower abdomen (2 inches lateral to the navel), anterior thigh (mid-quadriceps), or posterior upper arm (triceps region). Rotate sites to prevent lipohypertrophy (localized fat accumulation from repeated insulin-like signaling). Use a 29–31 gauge insulin syringe, pinch the skin to create a subcutaneous pocket, insert at 45–90 degrees, inject slowly, and hold for 5 seconds before withdrawing. Do not massage the injection site. It accelerates absorption unpredictably and disrupts the controlled-release kinetics.

CJC-1295 No DAC & Ipamorelin Dosage: Protocol Comparison

Key Takeaways

• CJC-1295 no DAC at 100–200mcg combined with Ipamorelin at 100–200mcg produces synergistic GH pulses 3–5× baseline when both peptides saturate their respective pituitary receptors simultaneously.
• Dosing below 100mcg per peptide fails to achieve receptor saturation. You get partial activation but not the multiplicative synergy that makes the stack effective.
• Timing administration 30–60 minutes before sleep synchronizes exogenous GH release with natural nocturnal GH pulses during deep slow-wave sleep, amplifying the overnight anabolic window.
• Reconstituted peptides stored above 8°C undergo irreversible protein denaturation. A single temperature excursion renders the peptide inactive regardless of appearance.
• Frequency protocols of 5 days per week prevent receptor downregulation while maintaining elevated weekly GH exposure; 7-day protocols require periodic 2-week washouts every 12 weeks.

What If: CJC-1295 & Ipamorelin Dosage Scenarios

What If I Don't Feel Anything After My First Injection?

GH elevation is not subjectively perceptible in real-time. You won't 'feel' the pulse. The primary acute sensation some users report is mild flushing or warmth within 10–15 minutes of injection (due to transient vasodilation from ghrelin receptor activation), but absence of this sensation does not indicate the peptides aren't working. Serum GH peaks at 30–45 minutes post-injection and returns to baseline within 2–3 hours. Functional outcomes (improved recovery, enhanced lipolysis, better sleep quality) manifest over weeks, not minutes. If you're expecting an immediate stimulant-like effect, you're measuring the wrong endpoint.

What If I Accidentally Inject Air Into the Vial While Drawing?

Each time air is pushed into a sealed vial, it creates positive pressure that forces solution back through the needle bore on withdrawal. Carrying bacteria or particulates from the rubber stopper into the peptide solution. If you've already done this multiple times with the same vial, the contamination risk is cumulative. Discard the vial if you notice cloudiness, particulate matter, or discoloration. For future draws, use the vacuum technique: insert the needle, invert the vial, and draw without injecting air. The slight vacuum is harmless and prevents contamination entirely.

What If I Miss My Scheduled Evening Dose?

If you miss a dose by fewer than 3 hours (e.g., you normally inject at 10 PM and remember at 12:30 AM), administer the dose immediately. The GH pulse will still coincide with late-stage slow-wave sleep. If more than 3 hours have passed or you're already past your first REM cycle, skip the dose and resume your regular schedule the following evening. Do not double-dose to 'catch up'. Administering 200mcg of each peptide when your protocol calls for 100mcg doesn't produce twice the GH release, it increases side effect risk (transient hyperglycemia, water retention) without additional efficacy.

What If I Want to Switch from CJC-1295 DAC to the No DAC Version?

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6–8 days, meaning it takes 4–5 weeks to fully clear from the body after discontinuation. If you've been using the DAC version and want to switch to no DAC, implement a 4-week washout period before starting the new protocol. Overlapping the two compounds creates unpredictable receptor occupancy. The DAC version continuously saturates GHRH receptors at low levels, preventing the pulsatile receptor activation that the no DAC version requires for synergistic amplification with Ipamorelin. The switch isn't a simple substitution. It requires a reset period.

The Clinical Truth About CJC-1295 & Ipamorelin Synergy

Here's the honest answer: most peptide users waste money by underdosing both compounds in the mistaken belief that 'low and slow' is safer or more sustainable. It's not. Below 100mcg per peptide, you're not triggering the receptor saturation required for synergistic amplification. You're administering two separate weak GH secretagogues that produce measurable but unimpressive results. The mechanism of synergy is conditional, not automatic.

The second uncomfortable truth: if you're dosing correctly but not structuring sleep, nutrition, and training around the GH pulse, you're negating most of the benefit. GH is catabolic in the short term (it mobilizes fatty acids and glucose for fuel) and anabolic in the long term (it stimulates IGF-1 synthesis in the liver, which drives tissue repair and growth). If you inject at 10 PM, stay up until 2 AM scrolling, and eat a high-carb meal at midnight, you've just blunted the GH pulse with insulin, disrupted the anabolic window with poor sleep quality, and wasted the injection. The peptide stack is a tool. Not a replacement for foundational health practices.

The third reality nobody mentions: individual response variance is significant. Some users achieve 5× baseline GH elevation at 100mcg per peptide; others need 200mcg to reach the same peak. This isn't about 'responders vs non-responders'. It's about baseline somatotroph sensitivity, which varies with age, body composition, insulin sensitivity, and chronic stress load. If 100mcg produces suboptimal results after 4–6 weeks, escalate to 150mcg per peptide before assuming the stack 'doesn't work for you.'

CJC-1295 no DAC paired with Ipamorelin is the most research-validated GH secretagogue stack available. But it requires precise dosing, correct timing, proper storage, and structured lifestyle factors to deliver the results the clinical literature demonstrates. Half-measures produce half-results.

If the pellets concern you, raise it before choosing your peptide source. Specifying a verified supplier like Real Peptides costs nothing extra upfront and matters across a multi-month protocol. Their CJC1295 Ipamorelin 5MG 5MG is formulated with exact amino-acid sequencing under USP standards. The difference between effective dosing and wasted injections often comes down to peptide purity verification most suppliers skip entirely.